Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Preclinical Development of OCF001 for Treatment of Yeast Infections

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary OccidiofunginsA Dare cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungiOptimization of the production and isolation of occidiofungins from liquid cultures has been performedThe production and isolation of predominantly one analogcalled occidiofungin BOCFsupports its commercial development as a novel antifun ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a novel accurate therapy for Multiple Sclerosis

    SBC: Autoimmunity Biologic Solutions, Inc.            Topic: NIAID

    PROJECT SUMMARY Multiple SclerosisMSis the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous systemresulting in progressive neurological dysfunctionUp to datethere is no cure for the disease and current available treatments focus on preventing future immunological attacksprimarily by su ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Personalized Bioreactor for Cell Culturing in Alginate Tubes

    SBC: CellGro Technologies, LLC            Topic: 400

    PROJECT SUMMARY ABSTRACT SignificanceCell therapy is expected to become an important method to treat chronic diseases such as diabetesrheumatoid arthritisretinal diseases like macular degeneration and certain types of cancersThe cell therapy market in general is projected to become a $billion industry byHuman pluripotent stem cellshPSCsare of particular importance since their utility as a source f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Carbidopa, an iron chelator and an ABCG2 inducer, for treatment of gouty arthritis

    SBC: South Plains Biotechnology, Inc            Topic: NIAMS

    Our goal is to evaluate the efficacy of the FDA approved drug Carbidopa for the treatment of gouty arthritis in mouse modelsCarbidopa is used to treat Parkinson s diseasebut always in combination of L DOPAnever alone by itselfGouty arthritis is caused by deposition of monosodium urateMSUcrystals in jointsinitiating inflammation and arthritisInterestinglygout is not always directly related to incre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Granulocyte/Monocyte Precursors to Treat Neutropenia after Cancer Chemotherapy

    SBC: Cord Blood Plus, Inc.            Topic: 102

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to move our product forward toward commercialization by improving the quality of life for breast cancer chemotherapy patientsThis will be achieved by the following Specific AimsAimwill optimize differentiation of GMPs and neutrophil lineages in culture in response to G CSFThis will be assessed by flow cytometry to quantify production of ne ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons

    SBC: SensoDX II, LLC            Topic: NIDA

    Abstract Opioid abuse disorderOADaffectsmillion of Americans annually resulting in overdoses numbering in the tens of thousands and skyrocketing rates of mortalityIn addition to its enormous social impactOAD carries a multi billion dollar price tag that includes $billionspecifically for health care and other costs related to prescription opioid abuse and misuseAlthough effective interventions exis ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Me & You-Tech: A socio-ecological solution to teen dating violence for the digital age.

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    ABSTRACT The goal of thisyear Fast Track STTR is to develop and evaluate a multi levelyouthparentschoolInternet based dating violenceDVprevention programMe andampYou TechMYTforthgrade middle school studentsByth gradeapproximatelyof students will have engaged in a dating relationshipOf thesealmost one third will have perpetrated physical DV and almost two thirds will have perpetrated emotional DVYo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Resveratrol as a Corneal Pain Therapeutic

    SBC: TED'S BRAIN SCIENCE INCORPORATED            Topic: N

    More thanindividuals undergo laser vision correction surgery each year in the United Statesincluding laser assisted in situ keratomileusisLASIKand photorefractive keratectomyPRKThese procedures damage the nerves in the corneal epithelium causing intense acute pain that most patients rate as greater thanon ascalemany report the pain to beunbearableeven after analgesic treatmentWhile virtually all p ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing

    SBC: Bondwell Technologies Inc.            Topic: 400

    Therapeutic antibodies have had a profound impact on treatment of many types of cancer and autoimmune diseasesAs a resultfive of the top ten best selling drugs ofwere therapeutic antibodiesMore than seventy therapeutic antibodies have been approvedand over six hundred antibody based products are in clinical developmentHoweverantibodies are extremely expensive to produceand large amounts of antibod ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIAMS

    Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government